Ask My Investor AI
Private companyPublished company research
PRIVATE

Current official releases identify NorthStar, LLC as a privately held Beloit, Wisconsin radiopharmaceutical company. No listed security, exchange or public-company CIK is asserted.

NorthStar, LLC

NorthStar is a private radiopharmaceutical and isotope-production pure-play. In January 2026 it reported routine weekly millicurie-scale production of non-carrier-added Ac-225 using electron-accelerator technology, and in April 2026 it reported FDA acceptance of the related Drug Master File. The operating capability is directly supported and highly relevant to an isotope-constrained supply chain, but production economics, capacity utilization, audited financials, a public security and licensed valuation are unavailable. The subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
private
Ticker
None
Exchange
None
HQ
United States
Currency
n/a
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

NorthStar combines electron-accelerator isotope production, generator-based Ac-225 supply, cGMP readiness and radiopharmaceutical CDMO/CMO capabilities on one campus. The non-uranium approach and accepted Drug Master File may lower customer qualification friction, but official sources do not disclose revenue, margins, contracted volume or competitive cost position.

Scarce assets

Electron-beam accelerators, isotope-processing facilities, non-carrier-added Ac-225 production know-how, cGMP systems, an FDA-accepted Drug Master File, Radium-226 feedstock arrangements and radiopharmaceutical development/manufacturing capability.

Products, segments, and customers

NorthStar develops and supplies radioisotopes including non-carrier-added Ac-225 and Cu-67 and provides radiopharmaceutical CDMO/CMO services. Public segment financial reporting is unavailable.

Theme capture

The company is definitionally exposed to medical-isotope production and radiopharmaceutical manufacturing. Weekly millicurie-scale Ac-225 production and an FDA-accepted DMF directly support capability, but no public financial evidence permits assessment of enterprise-scale materiality or value capture.

Conditions

What must be true

  1. Weekly Ac-225 production must scale reliably while meeting radionuclidic-purity and cGMP requirements.
  2. Clinical and commercial partners must convert supply agreements and DMF references into sustained contracted demand.
  3. Feedstock, accelerator uptime and generator logistics must support competitive cost and dependable delivery.

Identifiable catalysts

  • Additional clinical or commercial Ac-225 supply agreements.
  • Customer use of the accepted Drug Master File in IND or NDA submissions.
  • Disclosure of capacity, utilization, contracted volumes, financing or public-market plans.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Non-uranium isotope production and radiopharmaceutical CDMO/CMO services, centered on non-carrier-added Ac-225.

Medical isotopes and radiopharmaceutical logistics

Direct, definitionally material operating exposure. NorthStar reports routine weekly millicurie-scale non-carrier-added Ac-225 production using electron accelerators and an FDA-accepted Drug Master File supporting partner regulatory submissions.

Evidence
Current official releases support production cadence, technology, cGMP/DMF readiness and supply partnerships. They do not disclose revenue, margin, installed capacity, utilization or contracted commercial volume.
Materiality
disclosed — NorthStar is a private isotope and radiopharmaceutical pure-play, so operating exposure is definitional; financial materiality and valuation cannot be assessed from public statements.
Financial evidence

Official public disclosures

Reference period: 2026 operating disclosures.

  • Ac-225 production cadencemillicurie-level quantities on a weekly cycle
    January 2026 disclosure[2]
  • Ac-225 regulatory readinessFDA accepted NorthStar's no-carrier-added Ac-225 Drug Master File
    April 2026 disclosure[3]

Limitation: These are operating and regulatory milestones, not financial results. NorthStar publishes no reusable revenue, margin, cash-flow, leverage, capacity-utilization or valuation evidence.

Risks

Material risks and break conditions

Material risks

  • Private ownership and absent financial statements prevent assessment of liquidity, leverage and funding runway.
  • Accelerator uptime, Radium-226 feedstock, isotope purity and cGMP compliance are critical single-point operating risks.
  • Competing Ac-225 capacity may compress pricing before clinical demand reaches scale.

Thesis-break conditions

  • NorthStar cannot sustain weekly commercial-scale Ac-225 production or loses regulatory acceptability.
  • Partner programs fail to convert into durable commercial volume.
  • New supply removes scarcity faster than targeted-alpha therapy demand grows.
Investability conclusion

Where the evidence lands

NOT_READY and not directly investable through a public security. Official sources verify current Ac-225 production and FDA Drug Master File acceptance, but public financials, capacity economics, licensed valuation and human reviewer acceptance are absent.

Next diligence

  1. Obtain installed and usable Ac-225 capacity, yield, utilization and contracted-volume evidence.
  2. Review feedstock security, accelerator redundancy and partner concentration.
  3. Track NorthStar as a private supply-chain benchmark unless a public security becomes available.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. NorthStar corporate siteNorthStar, LLC · primary · published 2026-04-15 · accessed 2026-07-29
  2. NorthStar confirms successful routine commercial-scale Ac-225 productionNorthStar, LLC · primary · published 2026-01-06 · accessed 2026-07-29
  3. NorthStar secures FDA acceptance of Drug Master File for no-carrier-added Actinium-225NorthStar, LLC · primary · published 2026-04-15 · accessed 2026-07-29